Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909265 | 0.91 | PDE5A (0.42) | PDE5AMRGPRX4SCN9APLAUHTR5A | |
| SCHEMBL9925448 | 0.88 | HTR5A (0.52) | PDE5AMRGPRX4HTR5AEGLN1MEN1 | |
| SCHEMBL9909230 | 0.86 | MEN1 (0.44) | SCN9AHTR5AROCK2ROCK1MEN1 | |
| SCHEMBL9909242 | 0.86 | HTR5A (0.59) | PDE5ASCN9APLAUHTR5A | |
| SCHEMBL9909232 | 0.84 | EGLN2 (0.44) | PDE5AMRGPRX4PLAU | |
| SCHEMBL16509509 | 0.83 | MRGPRX4 (0.45) | MRGPRX4SCN9APLAULRRK2ROCK2 | |
| SCHEMBL9925238 | 0.83 | HTR5A (0.49) | PDE5ASCN9APLAUHTR5ALRRK2 | |
| SCHEMBL12874529 | 0.83 | PLAU (0.48) | PDE5AMRGPRX4SCN9APLAUHTR5A | |
| SCHEMBL9909208 | 0.81 | SCN9A (0.51) | PDE5AMRGPRX4SCN9AEGLN1 | |
| SCHEMBL9909273 | 0.79 | HTR5A (0.44) | SCN9AHTR5AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PDE5A 82/4885MRGPRX4 1163/4885SCN9A 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.